[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cormedix Inc (CRMD)

Cormedix Inc (CRMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 592,237
  • Shares Outstanding, K 78,442
  • Annual Sales, $ 311,710 K
  • Annual Income, $ 163,060 K
  • EBIT $ 150 M
  • EBITDA $ 166 M
  • 60-Month Beta 1.46
  • Price/Sales 2.00
  • Price/Cash Flow 3.88
  • Price/Book 1.54

Options Overview Details

View History
  • Implied Volatility 56.00% (+0.41%)
  • Historical Volatility 40.38%
  • IV Percentile 6%
  • IV Rank 15.54%
  • IV High 126.72% on 07/09/25
  • IV Low 42.99% on 08/15/25
  • Expected Move (DTE 31) 0.77 (9.82%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 3,452
  • Volume Avg (30-Day) 1,299
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 48,085
  • Open Int (30-Day) 66,251
  • Expected Range 7.03 to 8.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.25
  • Number of Estimates 2
  • High Estimate $0.26
  • Low Estimate $0.24
  • Prior Year $0.28
  • Growth Rate Est. (year over year) -10.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.27 +6.26%
on 04/24/26
8.94 -13.59%
on 05/14/26
+0.34 (+4.53%)
since 04/17/26
3-Month
6.13 +26.12%
on 03/06/26
8.94 -13.59%
on 05/14/26
+0.55 (+7.74%)
since 02/18/26
52-Week
6.13 +26.12%
on 03/06/26
17.43 -55.68%
on 06/23/25
-4.55 (-37.09%)
since 05/16/25

Most Recent Stories

More News
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences

PARSIPPANY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that management will be participating in fireside chats and investor meetings at both the RBC Capital...

CRMD : 7.78 (+3.05%)
CorMedix Q1 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while management...

CRMD : 7.78 (+3.05%)
CorMedix: Q1 Earnings Snapshot

CorMedix: Q1 Earnings Snapshot

CRMD : 7.78 (+3.05%)
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

‒ Q1 2026 Net Revenue of  $127.4 million ‒ ‒ Q1 2026 Net Income of $38.6 million ; Adjusted EBITDA of $70.0 million ‒ ‒ Company raises FY 2026 Revenue and Adjusted EBITDA...

CRMD : 7.78 (+3.05%)
CorMedix Guidance Already Slashed Expectations So Low That Beating Them May Mean Nothing

Barchart Research What to Expect from CRMD Earnings CRMD Generated May 13, 2026 Current Price $7.50 EPS Estimate $$0.34 Consensus Rating Moderate Buy Average Move 17.05% CorMedix Guidance Already Slashed...

CRMD : 7.78 (+3.05%)
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026

PARSIPPANY, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the first quarter ended March 31, 2026, before the...

CRMD : 7.78 (+3.05%)
CorMedix Reports Earnings Two Months Before Its Reimbursement Model Changes Completely

Barchart Research What to Expect from CRMD Earnings CRMD Generated May 4, 2026 Current Price $7.90 EPS Estimate $$0.34 Consensus Rating Moderate Buy Average Move 17.05% CorMedix Reports Earnings Two Months...

CRMD : 7.78 (+3.05%)
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients

– The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal free survival at Day 90 – – Study showed favorable benefit for toxicity related discontinuations...

CRMD : 7.78 (+3.05%)
CorMedix to Participate in Needham Virtual Healthcare Conference

PARSIPPANY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening...

CRMD : 7.78 (+3.05%)
CorMedix: Q4 Earnings Snapshot

CorMedix: Q4 Earnings Snapshot

CRMD : 7.78 (+3.05%)

Business Summary

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed...

See More

Key Turning Points

3rd Resistance Point 8.71
2nd Resistance Point 8.46
1st Resistance Point 8.01
Last Price 7.78
1st Support Level 7.30
2nd Support Level 7.05
3rd Support Level 6.60

See More

52-Week High 17.43
Fibonacci 61.8% 13.11
Fibonacci 50% 11.78
Fibonacci 38.2% 10.44
Last Price 7.78
52-Week Low 6.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.